MedTrace Logo

BPDO-1603 Intervention Trial in Patients With Moderate-to-severe Alzheimer's Disease

NCT04229927 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 712

Last updated 2020-04-22

No results posted yet for this study

Summary

A multicenter, randomized, double-blind, active-controlled, phase III clinical trial to evaluate the efficacy and safety of BPDO-1603 in patients with moderate-to-severe Alzheimer's disease

Conditions

  • Moderate-to-severe Alzheimer's Disease

Interventions

DRUG

BPDO-1603

Arm1 : 1 tablet of the test drug, and 1 tablet of placebo reference drug Arm2 : 1 tablet of the reference drug, and 1 tablet of placebo test drug

Sponsors & Collaborators

  • Hyundai Pharmaceutical Co., LTD.

    lead INDUSTRY

Principal Investigators

  • Seonghye CHOI · Inha University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-27
Primary Completion
2022-02-28
Completion
2023-03-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04229927 on ClinicalTrials.gov